Agilent’s Nucleic Acid Solutions Division (NASD) is located in Boulder, CO where it operates a 77,000 square foot multi-product cGMP oligonucleotide manufacturing facility. The company has acquired a 20 acre plot in Frederick, Colorado where construction of a new pharmaceutical facility will be completed in 2018 and cGMP operations will commence in 2019. The expansion will more than double Agilent’s commercial manufacturing capacity for nucleic acid based therapeutics.
Find us at the event
- Stand number